Sarepta shares fall 9.2% after Vinay Prasad returns as FDA CBER director

Sarepta Therapeutics shares fell 9.2% to $16.56 in pre-market trading on November 8, 2026, after Vinay Prasad returned as director of the FDA's Center for Biologics Evaluation and Research, the agency that oversees gene therapies.

Detected & updated continuously · Source: Nebula